AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

CEACAM1

Summary

CEACAM1 antibodies for anti-viral therapy: immune response against viruses is specific and allows an application to a broad range of viruses.

Technology Benefits

Complementary anti-viral therapy Option
Applies to a broad range of viruses
Specific immune response against specific viruses

Technology Application

therapeutic development

Detailed Technology Description

The approach is based on a antibody-mediated stimulation of the carcino-embryonic antigen-related cell adhesion molecule 1 (CEACAM1), which activates early parts of both the B cell and T cell receptor-induced signal transduction. The researchers have shown on the example of the lymphocytic choriomeningitis virus (LCMV) that these antibodies stimulate the activation and expansion of virus specific cytotoxic T cells, which comes along with a reduced virus load in serum and organs of mice. In vitro studies confirmed efficacy also against influenza virus and cytomegalovirus.

Type of Cooperation

Licensing

Application Date

28.07.2016

Application No.

US201615221612 20160728

Classes

- international:
C07K16/28; C12N5/0783
- cooperative:
A61K38/177; A61K39/095; A61K39/102; A61K39/1045; C07K16/2803; C12N5/0638; C07K2317/24; C07K2317/565; C07K2317/75; C07K2317/76; C07K2317/92; C07K2319/30; C12N2501/58; Y02A50/466

Others

Patent application

ID No.

4782

Country/Region

Germany

For more information, please click Here